The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | The use of viral-specific T-cells post bone marrow transplantation
Susan Prockop, MD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the use of viral-specific T-cells (VSTs) following bone marrow transplantation (BMT). In comparison to other cellular therapies, VSTs have minimal toxicity and do not induce high rates of graft-versus-host disease (GvHD). Dr Prockop introduces the data that she is going to present at R-HSCT², which includes clinical trials demonstrating the efficacy of third-party VSTs in patients with Epstein-Barr virus (EBV)-associated lymphoid malignancies. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
